N Katakami, M Matsuhisa, H Kaneto, T … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Circulating esRAGE levels were significantly lower in subjects with
type 1 diabetes than in nondiabetic subjects (0.266 ± 0.089 vs. 0.436 ± 0.121
ng/ml, respectively, P < 0.0001) and was inversely correlated with HbA 1c ... Cited by 64 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org H Koyama, T Shoji, H Yokoyama, K Motoyama, … - Arteriosclerosis, thrombosis, and vascular biology, 2005 - Am Heart Assoc Methods and Results— Plasma esRAGE was inversely associated with carotid or
femoral atherosclerosis, as quantitatively measured as intimal-medial thickness
(IMT) by arterial ultrasound. Stepwise regression analyses revealed that ... Cited by 92 - Related articles - All 7 versions
- ►ahajournals.org C Falcone, E Emanuele, A D'Angelo, MP Buzzi, … - Arteriosclerosis, thrombosis, and vascular biology, 2005 - Am Heart Assoc Methods and Results— Plasma levels of sRAGE were determined in 328 nondiabetic
male patients with angiographically proved CAD and in 328 age-matched healthy
controls. The concentration of sRAGE in plasma was significantly lower ... Cited by 112 - Related articles - All 11 versions
- ►ahajournals.org BI Hudson, E Harja, B Moser, AM Schmidt - Arteriosclerosis, thrombosis, and vascular biology, 2005 - Am Heart Assoc In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Falcone and
colleagues take the next step in linking RAGE to human atherosclerosis. In two
distinct populations of age-matched Italian male subjects without diabetes, ... Cited by 40 - Related articles - All 7 versions
- ►endojournals.org G Basta, AM Sironi, G Lazzerini, S Del Turco, E … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Results: Plasma sRAGE was lower in diabetic patients than controls [141
(53–345) vs. 735 (519–1001) pg/ml, median (interquartile range), P <
0.0001], whereas CML levels were higher in diabetic patients than controls ... Cited by 42 - Related articles - BL Direct - All 3 versions
H Koyama, T Shoji, S Fukumoto, K Shinohara, … - Arteriosclerosis Thrombosis and Vascular Biology, 2007 - Am Heart Assoc Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone:
410-528-4050. Permissions: Permissions & Rights Desk, Lippincott Williams &
Wilkins, a division of Wolters ... Low Circulating Endogenous Secretory ... Cited by 32 - Related articles - All 7 versions
PM Humpert, S Kopf, Z Djuric, T Wendt, M … - Diabetes Care, 2006 - Am Diabetes Assoc The receptor for advanced glycation end products (RAGE) has been shown to be
involved in the pathogenesis of late diabetes complications (1–5; rev. in 6).
However, little is known about the physiologic function of endogenous ... Cited by 18 - Related articles - BL Direct - All 5 versions
S Sakurai, Y Yamamoto, H Tamei, H Matsuki, … - Diabetes research and clinical practice, 2006 - Elsevier We recently identified a naturally occurring soluble form of RAGE (the receptor
for advanced glycation endproducts, receptor for AGE) in cultured human vascular
cells, and named it endogenous secretory RAGE (esRAGE). esRAGE is generated ... Cited by 33 - Related articles - All 10 versions
D Geroldi, C Falcone, E Emanuele, A D'Angelo … - Journal of hypertension, 2005 - journals.lww.com Objectives: Advanced glycation end-products (AGE) may cause vascular stiffening
by forming crosslinks through the collagen molecule or by interaction with their
cellular transductional receptor (RAGE). A secreted isoform of RAGE, termed ... Cited by 59 - Related articles - All 9 versions
- ►nih.gov [PDF] H Yonekura, Y Yamamoto, S Sakurai, RG … - Biochemical Journal, 2003 - pubmedcentral.nih.gov The binding of advanced glycation end-products (AGE) to the receptor for AGE
(RAGE) is known to deteriorate various cell functions and is implicated in the
pathogenesis of diabetic vascular complications. In the present study, we ... Cited by 243 - Related articles - BL Direct - All 8 versions
